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doi:10.1016/j.jfma.2011.07.004Background/Purpose: Ventilator-associated pneumonia (VAP) caused by Acinetobacter bau-
mannii has contributed to high mortality rate, prolonged stays in the intensive care unit,
and the rapid development of antimicrobial resistance to commonly used antimicrobials. This
study sought to determine predictors of mortality and carbapenem resistance for patients with
A baumannii VAP.
Methods: We retrospectively reviewed 541 adult patients with A baumannii pneumonia, who
were admitted to a medical center between 2005 and 2007; of which 180 (33.3%) had been
treated with mechanical ventilation. Of the 180 patients, 98 (54.4%) who survived were cate-
gorized as the survivor group, and 82 (45.6%) who died as the mortality group. Eighty-seven
(48.3%) with imipenem-sensitive A baumannii VAP were categorized as the IS-AB group, and
the remaining 93 (51.7%) with imipenem-resistant VAP as the IR-AB group.
Results: Compared with the survivor group, the mortality group had significantly higher Charl-
son comorbidity index scores, and more neoplastic disease, other sites of infection, blood-
stream infections, altered mental status, confusion, urea >7 mmol/L, respiratory rate
>30/min, low blood pressure (systolic <90 mmHg or diastolic <60 mmHg), age >65 years
(CURB-65)  3, creatinine > 1.6 mg/dL, C-reactive protein  100 mg/L, and imipenem resis-
tance. The survivor group had more cases of tracheostomy and diabetes mellitus than the
mortality group had. Compared with the IS-AB group, the IR-AB group had higher Charlson co-
morbidity index scores, longer stays before VAP onset, an increase in other sites of infection,
white blood cell count <4/mL or >1.1  104/mL, and higher hospital mortality rates.mh.org.tw (C.-C. Wang).
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Mortality risk factors in A baumannii pneumonia 565Conclusion: Inadequate initial empiric antimicrobial therapy and higher disease severity
scores, including CURB  3 and C-reactive protein  120 mg/L, were independent risk factors
associated with higher mortality rates for A baumannii pneumonia. Length of stay before VAP
and white blood cell count <4/mL or >1.1  104/mL were independent risk factors for carba-
penem resistance.
Copyright ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Hospital-acquired pneumonia (HAP) and ventilator-
associated pneumonia (VAP) are important causes of noso-
comial infections that are associated with high morbidity
and mortality rates. The attributive mortality has been
estimated as 33e50%, particularly in critically ill patients.1,2
VAP refers to pneumonia that develops more than 48e72
hours after intubation with mechanical ventilation.2,3 For
most patients with HAP, the pneumonia is diagnosed by
clinical manifestations, chest radiographic presentations,
and/or sputum culture. Bronchoscopy is not available for all
patients with HAP, thus the exact pathogen is difficult to
culture from sputum in patients with HAP.4 The incidence of
colonization in hospitalized patients is high;5 furthermore,
a positive culture cannot always distinguish a pathogen from
a colonizing organism. However, sterile culture by means of
bronchoscopy from the lower respiratory tract in an intu-
bated patient has been suggested.6
Acinetobacter baumannii, an aerobic Gram-negative
bacillus, is one of the most important nosocomial patho-
gens. The phenomenon of rapid development of antimi-
crobial resistance to commonly used antimicrobial agents
has been reported worldwide in recent years.7 Carbape-
nems are some of the most effective antibiotics used to
treat severe A baumannii infection. Unfortunately, an
increasing prevalence of carbapenem-resistant pathogens
has been observed in patients with HAP, especially in crit-
ically ill patients;8 however, the potential predictors of
carbapenem-resistant pneumonia have not been clearly
investigated. The aim of this study was to investigate the
risk factors of mortality in critically ill patients with A
baumannii pneumonia. We also analyzed the risk factors
and clinical differences between carbapenem-resistant and
carbapenem-sensitive A baumannii pneumonia in critically
ill patients.
Materials and methods
Study design
We conducted a retrospective observational study at
KCGMH. KCGMH is a 2500-bed medical facility serving as
a primary care and tertiary referral center in Kaohsiung,
Taiwan. We reviewed all the medical records of the
patients with A baumannii pneumonia admitted to KCGMH
between January 2005 and December 2007. Adult patients
(18 years old) with a first episode of A baumannii VAP
were included in our study. The patient’s exclusion criteria
included: (1) no first episode of A baumannii VAP; (2) Abaumannii isolated in the absence of clinical disease or
chest X-ray findings, which suggested colonization; (3)
sputum sample collection was not from the tracheostomy or
endotracheal tube after immediate intubation; and (4)
known tuberculosis or severe immunosuppression, such as
human immunodeficiency virus or solid organ or bone
marrow transplantation.
Definitions
HAP was defined as pneumonia that occurred within 48
hours after admission or if the patient was readmitted
within a week after the last discharge. VAP was defined as
pneumonia that occurred within 48 hours after commencing
mechanical ventilation.2,3 Pneumonia was defined accord-
ing to the criteria of the US Centers for Disease Control and
Prevention. Pneumonia required two or more of the
following criteria to be satisfied: (1) fever (increase of 1C
or body temperature >38.3C); (2) leukocytosis (25%
increase and 10,000/mm3) or leukopenia (25% decrease
and 5000/mm3); and (3) purulent tracheal secretion (>25
neutrophils per high power field). It also required one of
following criteria: (1) new or persistent infiltration on chest
radiography; (2) some microorganisms isolated from pleural
effusion and tracheal secretion; (3) radiographic cavitation
or histological evidence of pneumonia pathogens; or (4)
positive sputum culture from a quantitative bacterial
bronchoalveolar lavage culture of 105 colony-forming units/
mL. Intensive care unit (ICU) stay was defined as the
number of days the patient stayed in the ICU after A bau-
mannii had been isolated from sputum. The susceptibility
of A baumannii isolates to antimicrobial agents was
determined by using the disk-diffusion test as recom-
mended by the National Committee for Clinical Standards.9
Indeterminate susceptibility to antimicrobials was consid-
ered as resistance, excluding cases in which the specimens
and/or cultures had been contaminated.
Previous antimicrobial therapy was defined as receiving
a systemic antimicrobial agent for at least 48 hours in the 2
weeks preceding sputum culture collection. Antimicrobial
therapy was considered to be appropriate if all pathogens
isolated from culture were sensitive to it and inadequate if
any pathogen was resistant to it. After 7 days of antimi-
crobial treatment, the pneumonia condition was re-
evaluated and classified as improved if the fever had
subsided, tracheal purulent secretion decreased, pneu-
monia consolidation or infiltration regressed on chest
radiography, and there was an improvement in laboratory
data [including white blood cells (WBCs) and C-reactive
protein (CRP)]. Otherwise, the clinical status after 7 days of
antibiotic treatment was identified as improved or not
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classified as not improved.
Data collection
The demographic characteristics including age, sex,
underlying disease or condition, length of hospital stay,
initial empirical antimicrobial therapy, susceptibility to
antimicrobial agents, and discharge status were reviewed
and obtained from medical charts. Information regarding
initial clinical and laboratory condition was also collected.
The Charlson comorbidity index, confusion, urea >7 mmol/
L, respiratory rate >30/min, low blood pressure (systolic
<90 mmHg or diastolic <60 mmHg), age >65 years (CURB-
65) score,10,11 other sites of infection, ICU stay, invasive
procedures (including those required for tracheostomy or
mechanical ventilation), and previous antimicrobial treat-
ment were considered as possible risk factors.
Statistical analysis
All statistical analyses were performed using SPSS version
14.0 software (Chicago, IL, USA). Categorical variables
were analyzed using the c2 test or Fisher’s exact test.
Continuous variables were compared using Student t test or
the ManneWhitney U test. Multivariate logistic regression
analyses were performed to identify the risk factors for
mortality and imipenem resistance. Each variable consid-
ered a risk factor, and with a p value <0.05 in the univar-
iate analysis, it was entered into the multivariate model.
The enter method was used to define the final independent
risk factors, and the Hosmer-Lemeshow test was used to
assess goodness-of-fit. A p value <0.05 was considered
statistically significant.
Results
A total of 541 adult patients with A baumannii pneumonia
were admitted to KCGMH between January 2005 and
December 2007. This included 180 (33.3%) patients with
intubation and mechanical ventilation. Among these 180
patients, 98 (54.4%) survived and were classified as the
survivor group, and 82 (45.6%) who died were classified as
the mortality group. Furthermore, 87 (48.3%) patients with
imipenem-sensitive A baumannii VAP were classified as the
IS-AB group, and the remaining 93 (51.7%) with imipenem-
resistant VAP were classified as the IR-AB group.
Comparisons between survivor and mortality
groups
Table 1 shows the comparisons of demographic and clinical
characteristics of patients with A baumannii VAP between
the survivor and mortality groups. There were no significant
differences in sex, age, previous antimicrobial therapy,
late-onset VAP, ICU stay, congestive heart failure, chronic
obstructive pulmonary disease, chronic liver or renal
disease, and presence of polymicrobial pneumonia between
both groups. Furthermore, there were significant differ-
ences in Charlson comorbidity index score, neoplasticdisease, other sites of infection, bloodstream infection,
altered mental status, CURB-65  3, blood urea nitrogen
>20 mg/dL, otherwise, creatinine >1.6 mg/dL, CRP 
100 mg/L, and imipenem resistance between both groups.
The incidences of patients with tracheostomy and diabetes
mellitus (DM) were significantly higher in the survivor group.
Patients in the survivor group received more adequate
empiric antibiotic treatment (p Z 0.017) and had a more
improved response (p < 0.001) than those in the mortality
group.
Comparisons between IS-AB and IR-AB groups
Table 2 shows the comparisons of demographic and clinical
characteristics of patients with A baumannii VAP between
the IS-AB and IR-AB groups. There were significant differ-
ences in Charlson comorbidity index score, length of stay
before VAP onset, other sites of infection, WBC count <4 mL
or >1.1  104/mL and hospital mortality rate between both
groups.
Copathogens and antimicrobial treatment
Fifty A baumannii VAP patients had copathogens. Pseudo-
monas aeruginosa (n Z 14, 28%), Staphylococcus aureus
(n Z 13, 26%) and Corynebacterium spp. (n Z 11, 22%)
were the three most frequent copathogens combined with
A baumannii infection (Table 3). The most frequently used
initially adequate antibiotics were carbapenems (41.46%)
and sulbactam (48.78%). Inadequate antibiotic therapy
included cephalosporins (35.25%), carbapenems (29.9%)
and quinolones (18.71%) in the distribution of clinical
differences in antimicrobial management. Decreasing
trends in the susceptibility rates of carbapenems (from
72.5% to 36%) and sulbactam (from 70% to 50.7%) were
observed (Table 4).
Risk factors for mortality associated with
A baumannii VAP
Multivariate analysis (Table 5) revealed that 30 days in-
hospital mortality, creatinine >1.6 mg/dL, inadequacy of
initial empirical antibiotics, CURB  3, and CRP  120 mg/L
were independent risk factors for the mortality group
(p < 0.05). Otherwise, tracheostomy and DM seemed to
provide some survival benefits. Multivariate analysis (Table
5) also revealed that the length of stay before VAP onset
and WBC count <4 mL or >1.1  104/mL were independent
risk factors for the IR-AB group.
Discussion
HAP is difficult to diagnosis; therefore, most patients with
pneumonia are diagnosed by clinical manifestations, chest
radiographic presentations, and/or sputum culture reports.
The sputum culture with a high incidence rate of coloni-
zation was observed in hospitalization patients. Instead,
a sterile sputum culture from the lower respiratory tract
was usually requested. One previous study reported that
sputum cultures by means of endotracheal tube aspiration
Table 1 Comparisons of demographic and clinical characteristics of patients with Acinetobacter baumannii ventilator-
associated pneumonia between the survivor and mortality groups
Survivor group n Z 98 (54.4%) Mortality group n Z 82 (45.6%) p
Demographics
M/F 56/42 52/30 0.392
Age (y) 70.4  13.5 68.8  16.0 0.463
Antibiotic in past 14 d 95 (97.9) 82 (100.0) 0.191
Late-onset VAP (5 d) 63 (64.3) 58 (70.7) 0.359
ICU stay 82 (83.7) 75 (91.5) 0.119
LOS 67.4  34.4 38.9  26.5 <0.001
Before VAP onset 28.6  24.2 30.8  25.5 0.538
After VAP onsetb 38.8  24.7 8.1  7.7 <0.001
Comorbidity
Charlson comorbidity indexb 2.86  1.98 3.53  2.19 0.033
Neoplastic diseaseb 17 (17.3) 31 (37.8) 0.002
CHF 22 (22.4) 13 (15.9) 0.266
Diabetes mellitusb 39 (39.8) 19 (23.2) 0.017
Chronic respiratory diseasea 22 (22.4 19 (23.2) 0.908
Liver diseasea 12 (12.2) 14 (17.1) 0.359
Renal diseasea 23 (23.5) 24 (29.3) 0.378
Clinical features
Polymicrobial infection 33 (33.7) 17 (20.7) 0.054
Other site of infectionb 25 (25.5) 44 (53.7 <0.001
Bloodstreamb 18 (18.4 39 (47.6 <0.001
Catheter 6 (6.1) 4 (4.9) 0.717
Urinary 8 (8.2) 6 (7.3 0.833
Other 0 (0.0) 3 (3.7) 0.093
Tracheostomyb 33 (33.7) 9 (11.0) <0.001
Altered mental statusb 22 (22.4) 37 (45.1) 0.001
CURB-65  3b 33 (33.7) 48 (48.8) 0.040
BUN  30 mg/dLb 42 (42.9) 60 (73.2) <0.001
Cr > 1.6 mg/dLb 26 (26.5) 45 (54.9) <0.001
WBC <4 or >1.1  104/mL 51 (52.0) 51 (62.2) 0.171
CRP  100 mg/Lb 29 (29.6) 40 (48.8) 0.008
Imipenem resistanceb 44 (44.9) 49 (59.8) 0.047
Ampicillin/sulbactam resistance 38 (38.8) 38 (46.3) 0.306
Initial antibiotic therapyb 0.017
Inadequate 69 (70.4) 70 (85.4)
Adequate 29 (29.6) 3 (3.7)
Pneumonia status within 7 d <0.001
Improved 61 (62.2) 8 (9.8)
Not improved 37 (37.8) 74 (80.2)
Data are represented as mean  standard deviation or n (%).
a Disease was defined as in the Charlson comorbidity index.
b Variable was entered into the multivariate logistic regression analysis.
BUN Z blood urea nitrogen; CHF Z congestive heart failure; Cr Z creatinine; CRP Z C-reactive protein; CURB-65 Z confusion, urea
>7 mmol/L, respiratory rate >30/min, low blood pressure (systolic <90 mmHg or diastolic <60 mmHg), age >65 years; ICUZ intensive
care unit; LOSZ length of stay; Other sites of infectionZAcinetobacter baumannii cultured from other than sputum; VAPZ ventilator-
associated pneumonia; WBC Z white blood cell.
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bronchoalveolar lavage in 83% of the patients with suspicion
of VAP, and provided adequate information for therapy in
95% of the patients.12 Therefore, we only enrolled patients
with A baumannii-positive sputum cultures obtained via
endotracheal tube aspiration, to avoid contamination.
Patients with tuberculosis were not enrolled in the study.
We excluded patients that were positive for acid-fast bacilliand A baumannii, because this could have led to confusion
between pathogenic and colonizing organisms.
The mean total duration of hospitalization in this study
was 47 days, which is slightly longer than that reported in
western countries (range: 29e40 days).13,14 A baumannii is
the pathogen that contributes to a significantly higher
mortality rate was compared to other nosocomial path-
ogen.15 The mortality rates associated with A baumannii
Table 2 Comparisons of demographic and clinical characteristics of patients with Acinetobacter baumannii ventilator-
associated pneumonia between imipenem-sensitive and imipenem-resistant groups
IS-AB group n Z 87 (48.3%) IR-AB group n Z 93 (51.7%) p
Demographics
M/F 55/32 53/40 0.394
Age (y) 70.9  13.6 68.5  15.6 0.279
Antibiotic in past 14 d 85 (97.7) 92 (98.9) 0.611
Late-onset VAP (5 d) 59 (67.8) 62 (66.7) 0.870
ICU stay 76 (87.4) 81 (87.1) 0.958
LOS 50.8  31.5 57.8  36.2 0.165
Before VAP onsetb 24.1  20.4 34.7  27.4 0.004
After VAP onset 26.7  24.3 23.1  24.3 0.331
Comorbidity
Charlson comorbidity indexb 2.76  1.97 3.56  2.16 0.010
Neoplastic disease 20 (23.0) 28 (30.1) 0.280
CHF 19 (21.8) 16 (17.2) 0.432
Diabetes mellitus 27 (31.0) 31 (33.3) 0.742
Chronic respiratory diseasea 20 (23.0) 21 (22.6) 0.948
Liver diseasea 10 (11.5) 16 (17.2) 0.276
Renal diseasea 21 (24.1) 26 (28.0) 0.560
Clinical features
Polymicrobial infection 30 (34.5) 20 (21.5) 0.052
Other site of infectionb 26 (29.9) 43 (46.2) 0.024
Bloodstream 22 (25.3) 35 (37.6) 0.075
Catheter 4 (4.6) 6 (6.5) 0.587
Urinary 4 (4.6) 10 (10.8) 0.123
Other 0 (0.0) 3 (3.2) 0.247
Tracheostomy 24 (27.6) 18 (19.4) 0.192
Altered mental status 25 (28.7) 34 (36.6) 0.264
CURB-65  3 31 (35.6) 42 (45.2) 0.193
BUN  30 mg/dL 47 (54.0) 55 (59.1) 0.489
Cr > 1.6 mg/dL 33 (37.9) 38 (40.9) 0.688
WBC <4 or >1.1  104/mLb 39 (44.8) 63 (67.7) 0.002
CRP  100 mg/L 27 (31.0) 42 (45.2) 0.051
Imipenem resistance d d d
Ampicillin/sulbactam resistance 31 (35.6) 45 (48.4) 0.083
Initial antibiotic therapy 0.674
Inadequate 66 (75.9) 73 (78.5)
Adequate 21 (24.1) 20 (21.5)
Pneumonia status within 7 d 0.124
Improved 40 (46.0) 29 (31.2)
Not improved 47 (54.0) 64 (68.8)
In-hospital mortalityb 40 (46.0) 57(61.3) 0.039
Data are represented as mean  standard deviation or n (%).
a Disease was defined as in the Charlson comorbidity index.
b Variable was entered into the multivariate logistic regression analysis.
ABZ imipenem-sensitive A baumannii; BUNZ blood urea nitrogen; CHFZ congestive heart failure; CrZ creatinine; CRPZ C-reactive
protein; CURB-65 Z confusion, urea >7 mmol/L, respiratory rate >30/min, low blood pressure (systolic <90 mmHg or diastolic
<60 mmHg), age >65 years; ICUZ intensive care unit; IS-IR-ABZ imipenem-resistant A baumannii; LOSZ length of stay; Other sites of
infectionZAcinetobacter baumannii cultured from other than sputum; VAP Z ventilator-associated pneumonia; WBC Z white blood
cell.
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studies,16,17 and it was 53.9% in our study. Whereas, the IR-
AB group had a significantly higher mortality rate than the
IS-AB group (pZ 0.039). This is different from other studies
that have shown that IR-AB is not associated with hospital
mortality.18In our study, polymicrobial infection was common in
nosocomial pneumonia caused by P aeruginosa, S aureus,
and Corynebacterium spp. These were the three most
frequently found copathogens combined with A baumannii
infection. The results showed that polymicrobial infection
was not associated with hospital mortality and carbapenem
Table 3 Distribution of copathogens with Acinetobacter baumannii pneumonia
Survivor group n Z 33 (66%) Mortality group n Z 17 (34%) p
Pseudomonas aeruginosa 8 (16) 6 (12) 0.833
Staphylococcus aureus 7 (14) 6 (12) 0.964
Corynebacterium spp. 11 (22) 0 (0) 0.001
Stenotrophomonas maltophilia 3 (6) 3 (6) 1.000
Klebsiella pneumoniae 1 (2) 1 (2) 1.000
Escherichia coli 0 (0) 1 (2) 0.456
Enterobacter spp. 1 (2) 0 (0) 1.000
Other 3 (6) 0 (0) 0.252
There were a total of 51 pathogens from 50 patients.
Data are represented as n (%).
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manifestation. However, polymicrobial infection is
frequently encountered in clinical practice. Thus, we could
not disregard the importance of polymicrobial infection as
a coinfection. Therefore, it is necessary to pay attention to
the presence of A baumannii in polymicrobial infection,
and careful selection of appropriate antibiotics for empir-
ical therapy of A baumannii pneumonia should also consider
copathogens. Carbapenem and sulbactam are effectively
therapeutic and frequently prescribed for the treatment
A baumannii pneumonia.19 However, in recent decades,
A baumannii has developed a remarkably rapid antibiotic
resistance, leading to multidrug-resistant pathogens with
limited therapeutic options.20,21 Carbapenems and third-
generation cephalosporins were not initially appropriate
antibiotics for nearly half of the patients with A baumannii
pneumonia in our study. This might have been because the
number of pathogens with antibiotic resistance has
increased, and that carbapenem and sulbactam suscepti-
bility rates have gradually decreased in recent years. Car-
bapenems and third-generation cephalosporins are
recognized as the most important risk factors for multidrugTable 4 In vitro susceptibility analysis of Acinetobacter bauma
Overall 2
Amikacin 11.1 1
Amoxicillin/clavulanic acid 0.0
Ampicillin/sulbactam 57.8 7
Aztreonam 0.0
Cefepime 6.7 1
Ceftazidime 5.6 1
Ceftriaxone 0.6
Cefuroxime 2.0
Cephalothin 0.0
Ciprofloxacin 3.3
Gentamicin 5.6 1
Imipenem 48.3 7
Piperacillin 1.8
Piperacillin/tazobactam 1.6
Sufamethoxazole/trimethoprim 3.9 1
Tigecycline 68.0resistance.22 Early and adequate antibiotic therapy are
important to optimize the management of HAP.7,9,23,24
Initially appropriate antibiotics are very important for
patients with HAP, especially for those with antibiotic-
resistant pathogens. Initially inappropriate antibiotic
therapy for VAP is associated with a significantly greater
incidence of 30 days in-hospital mortality.23 In our study,
the adequacy of initial empiric antibiotic therapy for
patients with A baumannii pneumonia was correlated with
hospital survival, and the inadequacy of initial antibiotic
therapy was an independent predictive factor for hospital
mortality by multivariate analysis. Lee et al15 have repor-
ted that the mortality rate is significantly higher in patients
with inappropriate initial empiric antibiotic therapy, even
when subsequent antibiotic therapy is appropriate. As long
as a good quality sputum culture is done as early as
possible, appropriate antimicrobial therapy has an impact
on the clinical outcome in patients with A baumannii
pneumonia. Sulbactam, tigecycline, and colistin represent
the present therapy associated with satisfactory efficacy.22
In our study, the tigecycline susceptibility rate of A bau-
mannii was only 68% in vitro in the first year.nnii
005 2006 2007
5.0 (6/40) 7.7 (5/65) 12.0 (9/75)
0.0 (0/40) 0.0 (0/12) d
0.0 (28/40) 58.5 (38/65) 50.7 (38/75)
0.0 (0/40) 0.0 (0/65) 0.0 (0/75)
5.0 (6/40) 7.7 (5/65) 1.3 (1/75)
5.0 (6/40) 6.2 (4/65) 0.0 (0/75)
2.5 (1/40) 0.0 (0/65) 0.0 (0/75)
2.5 (1/40) 0.0 (0/11) d
0.0 (0/40) 0.0 (0/11) d
7.5 (3/40) 4.6 (3/65) 0.0 (0/75)
2.5 (5/40) 6.2 (4/65) 1.3 (1/75)
2.5 (29/40) 47.7 (31/65) 36.0 (27/75)
5.0 (2/40) 1.5 (1/65) 0.0 (0/58)
d 3.8 (2/53) 0.0 (0/75)
0.0 (4/40) 4.6 (3/65) 0.0 (0/75)
d d 68.0 (17/25)
Table 5 Independent risk factors in multivariate analyses
Variables AOR (95% CI) p
Imipenem resistance
LOS prior to VAP onset (d) 1.02 (1.00e1.04) 0.012
WBC <4 or >1.1  104/mL 2.48 (1.31e4.72) 0.005
30-d mortality
Diabetes mellitus 0.34 (0.13e0.85) 0.022
Tracheostomy 0.20 (0.07e0.58) 0.003
Cr > 1.6 mg/dL 3.90 (1.26e12.08) 0.018
Inadequacy of initial
empiric antibiotic
4.06 (1.39e11.87) 0.010
CURB  3 13.22 (2.40e72.71) 0.003
CRP  120 2.63 (1.11e6.28) 0.029
AOR Z adjusted odd ratio; CI Z confidence interval;
CrZ creatinine; CRPZ C-reactive protein; CURBZ confusion,
urea >7 mmol/L, respiratory rate >30/min, low blood pressure
(systolic <90 mmHg or diastolic <60 mmHg); LOS Z length of
stay; VAP Z ventilator-associated pneumonia; WBC Z white
blood cell.
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mannii pneumonia is accompanied by bacteremia,7 and
that bacteremic pneumonia may clinically manifest from
benign transient to fulminant septic shock, which conse-
quently has a high mortality rate.25 Among our patients, the
incidence and mortality rates of bacteremia were 31.7%
and 47.6%, respectively.
Charlson comorbidity index, CURB-65, and CRP as inde-
pendent markers of severity scores have been used to
predict mortality in HAP.26,27 The identification of these
severity scores is useful in the recognition of the individual
clinical course and outcome. In our study, severity scores of
CURB  3, CURB-65  3, and CRP  100 mg/L had similar
area under the curve values. CURB-65  3 and
CRP  120 mg/L had higher specificity, positive predictive
value, and negative predictive value, and they were used
for multivariate analysis. In recent studies, malignancy,
septic shock, and organ failure have been shown to be
independent factors associated with mortality in A bau-
mannii infection.15 In our study, we found that creatinine
>1.6 mg/dL, CURB  3, and CRP  120 mg/L were inde-
pendent risk factors for mortality in patients with A bau-
mannii pneumonia. Moreover, it was not surprising that the
length of stay before VAP onset and WBC count <4 mL or
>1.1  104/mL were independent risk factors for imipenem
resistance. In a recent study, neutropenia and prolonged
use of carbapenem induced production of metallo-b-lac-
tamase, which then developed imipenem-resistant A bau-
mannii pathogens.28 However, an interesting finding in our
study was that DM was associated with a lower mortality
risk, which is in discordance with other reports.29 DM is
a common disease in the developed world and a cause of
disability. Impaired glucose metabolism has been associ-
ated with several complications, including induced leuko-
cyte adherence, chemotaxis, and phagocytosis dysfunction
of WBCs, which increases the development and mortality of
community-acquired pneumonia. In contrast, one review
has reported that DM is not a risk factor for the develop-
ment of HAP, nor increased mortality associated with
nosocomial complications.30 However, further research isneeded to help determining the impact of DM on the inci-
dence and/or severity of HAP.
Sputum cultures of the lower respiratory tract by means
of a tracheostomy tube are not contaminated by the normal
flora of the oral cavity, because liberation of the vocal
cords results in normal closure and reduces the risk of
aspiration of secretions from the oropharyngeal cavity.
However, based on the pathophysiology of VAP, tracheos-
tomy could be protective against VAP.31 Many researchers
have shown that tracheostomy decreases the risk of
VAP.32,33 Patients with early tracheostomy are associated
with lower rates of VAP and mortality as compared with
those with late tracheostomy.32 In our study, tracheostomy
was demonstrated to have a potentially significant protec-
tive effect in both univariate and multivariate analysis. A
possible explanation for this finding is that the patients who
received tracheostomy had a decreased risk of aspiration of
secretion and reduced mortality. The relationship between
VAP, disease severity and timing of tracheostomy and
intubation are still unclear, further investigations are
needed.
This retrospective study had several limitations. First,
this study was conducted at a single medical center, and
there may have been patient selection bias and referral
patterns. Second, this study was a retrospective survey,
which not only resulted in incomplete data for some
patients, but also did not control for laboratory examina-
tions and the clinical courses of all VAP patients. Therefore,
some important risk factors for VAP, such as re-intubation
and nutritional status, were not investigated. Further
prospective investigations should be conducted. Despite
these limitations, this study provides relatively rare data
regarding a series of VAP patients with A baumannii.
In conclusion, this study conducted a series-based study
of VAP patients with A baumannii cultured by means of
endotracheal tube aspiration. Inadequate initial empiric
antimicrobial therapy and higher severity scores, including
CURB  3 and CRP  120 mg/L, were independent risk
factors associated with a higher mortality rate for A bau-
mannii pneumonia. Length of stay and WBC <4/mL or
>1.1  104/mL were independent risk factors for carbape-
nem resistance. Further studies are needed to determine
the risk factors for antibiotic resistance in these patients.Acknowledgments
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